Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peptide-based immunotherapy in pre-operative window for head and neck squamous cell carcinoma
2020-000120-19Phase 2Active
- Sponsor
- Cliniques universitaires Saint-Luc
- Start
- Feb 2020
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of io102 and IO103 + Montanide in head and neck squamous cell carcinoma (HNSCC), sponsored by Cliniques universitaires Saint-Luc. Primary endpoint: T-cell peptide-specific response. Started Feb 2020; status: active.
02
Drugs
io102IO103 + Montanide
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2020-000120-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000120-19.